Goods & Services

Eyeliners; Make-up; Mascara; Adhesives for attaching artificial fingernails and/or eyelashes; Cosmetic pencils; Cosmetics, namely, lip primer; Eyebrow pencils; Make-up removing preparations; Nail care preparations; Nail enamels; Skin gels for accelerating, enhancing or extending tans; Skin masks; Skin moisturizer masks; Tooth whitening creams; face, body, hand moisturizers

Abstract

Disclosed in the present invention is the use of a recombinant soluble tumour necrosis factor α receptor (HusTNFR) gene as a new drug. The invention uses the long-acting human recombinant soluble tumour necrosis factor α receptor of type I or type II to intervene with rats with chronic liver diseases and severe liver damage through a five animal model, the results show that the long-term human recombinant soluble tumour necrosis factor α receptor having a half-life of 12-140 hours has a good effect for preventing the appearance of chronic liver disease and severe liver damage and treating early chronic liver disease and severe liver damage, and the efficacy thereof is significantly improved compared to non-long-term HusTNFR.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/28 - Tumor necrosis factors